目的 基于網(wǎng)絡(luò)藥理學(xué)方法研究枸杞子治療代謝相關(guān)脂肪性肝?。∕AFLD，曾用名非酒精性脂肪肝）主要活性成分的作用靶點(diǎn)及機(jī)制。方法 通過中藥系統(tǒng)藥理學(xué)數(shù)據(jù)庫（TCMSP）獲取枸杞子的活性成分，設(shè)定口服生物利用度（OB）≥30%和類藥性（DL）≥0.18，并篩選出枸杞子作用靶點(diǎn)，構(gòu)建成分-靶點(diǎn)網(wǎng)絡(luò)。通過GenCards數(shù)據(jù)庫篩選出枸杞子治療MAFLD的潛在作用靶點(diǎn)，利用Cytoscape軟件構(gòu)建疾病-成分-靶點(diǎn)可視化網(wǎng)絡(luò)圖，進(jìn)行基因本體論（GO）功能分析和京都基因和基因組百科全書（KEGG）通路富集分析。結(jié)果 獲得枸杞子活性成分45個(gè)，MAFLD差異基因1 656個(gè)，交集靶點(diǎn)87個(gè)，涉及60條通路，可能通過AKT1、IL6、IL1B等關(guān)鍵靶蛋白，參與DNA結(jié)合轉(zhuǎn)錄激活因子活性表達(dá)、RNA聚合酶Ⅱ特異性轉(zhuǎn)錄、肽鏈內(nèi)切酶活性等生物學(xué)過程，枸杞子可能通過作用于IL-17信號通路、AGE-RAGE信號通路、MAFLD信號通路等發(fā)揮治療MAFLD的作用。結(jié)論 枸杞子通過多成分、多靶點(diǎn)、多通路治療MAFLD。

Objective To explore the target and mechanism of Lycium barbarum in treatment of metabolic related fatty liver disease (non-alcoholic fatty liver disease) based on network pharmacology. Methods The chemical components and targets of Lycium barbarum were obtained from TCMSP databases, and the component-target network was constructed. GenCards databases were used to screen out the potential target of Lycium barbarum for treatment of metabolic related fatty liver disease. Cytoscape software was used to construct the network map of disease-component-target, and further analyze the gene GO function and KEGG pathway enrichment. Results Total 45 active components, 1 656 MAFLD differential genes and 87 intersecting targets were obtained from Lycium barbarum, involving 60 pathways. It may participate in biological processes such as active expression of DNA binding transcription activator, specific transcription of RNA polymerase II and endopeptidase activity through key target proteins such as AKT1, IL6 and IL1B. Lycium barbarum may act on IL-17 signal pathway, AGE-RAGE signal pathway MAFLD signaling pathway plays a role in the treatment of MAFLD. Conclusion Lycium barbarum can treat MAFLD through multi-component, multi-target and multi-channel.

R285